Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx -SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

  • Matthew Goldberg

Press/Media

Period25 Oct 2022

Media coverage

1

Media coverage

  • TitleCastle Biosciences Presents New Data Demonstrating the Impact of DecisionDx -SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date25/10/22
    URLmetabase.moreover.com/noarticleurl?type=psh&lni=66PH-KTJ1-JDG9-Y47V-00000-00
    PersonsMatthew Goldberg